KAS
TXMD icon

Kestra Advisory Services’s TherapeuticsMD TXMD Stock Holding History

Kestra Advisory Services’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-231
Closed -$14K – 2177
2021
Q2 		$14K Buy
+231
New +$14K ﹤0.01% 1993

Other funds holding TXMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Kestra Advisory Services's TXMD Position: Q3 2021 in Review

Kestra Advisory Services sold out of TherapeuticsMD (TXMD) in Q3 2021, closing a stake of 231 shares — an estimated $14K sold.

Kestra Advisory Services first reported a position in TXMD in Q2 2021 and held it in 1 quarter. The position peaked at $14K in Q2 2021. 149 funds tracked by Wall St. Rank hold TXMD as of Q3 2021.

  • Kestra Advisory Services reported no remaining TherapeuticsMD position as of Q3 2021 after selling out during the quarter.
  • Kestra Advisory Services sold 231 TherapeuticsMD shares in Q3 2021, an estimated $14K.
  • Kestra Advisory Services first reported a position in TherapeuticsMD in Q2 2021 and held it in 1 quarter.
  • Kestra Advisory Services's TherapeuticsMD position peaked at $14K in Q2 2021.
  • 149 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2021.

Based on Kestra Advisory Services's 13F filing for Q3 2021, filed 19 Oct 2021.